Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from DXCM

Earnings Preview: What To Expect From DexCom's Report

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage.

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

Is DexCom Stock Underperforming the Dow?

Is DexCom Stock Underperforming the Dow?

DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The DexCom Stock Turnaround Is Showing Real Signs of Life

DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...

Are Wall Street Analysts Bullish on DexCom’s Stock?

Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects.

3 Reasons Analysts Love DexCom

Continuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market.

DexCom’s Quarterly Earnings Preview: What You Need to Know

DexCom is set to report its first-quarter results at month-end, and the Street is expecting a solid double-digit expansion in earnings.

inkl

Read news from The Economist, FT, and more,
with one subscription

Is DexCom Stock Underperforming the Nasdaq?

Is DexCom Stock Underperforming the Nasdaq?

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.

What Are Wall Street Analysts' Target Price for DexCom Stock?

What Are Wall Street Analysts' Target Price for DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

DexCom's Q4 2025 Earnings: What to Expect

DexCom's Q4 2025 Earnings: What to Expect

DexCom will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Is DexCom Stock Underperforming the S&P 500?

Is DexCom Stock Underperforming the S&P 500?

DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom Stock: Is Wall Street Bullish or Bearish?

DexCom Stock: Is Wall Street Bullish or Bearish?

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL Education Inc (NYSE:TAL), Shake Shack Inc (NYSE:SHAK) and DexCom Inc (NASDAQ:DXCM).

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

Get all your
news in one place.

100's of premium titles.
One news app.

DexCom Earnings Preview: What to Expect

DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside

These two companies could present an opportunity for investors to gain access while they are relatively undervalued and before they appreciate once again.

How Is DexCom's Performance Compared to Other Medical Device Companies?

DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy

Wall Street gives these three diverse names Strong Buy recommendations with high potential upside.

What You Need to Know Ahead of DexCom’s Earnings Release

DexCom is all geared up to announce its second-quarter earnings towards the end of this month, and analysts anticipate a single-digit bottom-line growth.

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

DexCom Stock: Is DXCM Underperforming the Health Care Sector?

DexCom has underperformed the Health Care sector over the past year, but analysts are highly optimistic about the stock’s prospects.

What to Expect From DexCom's Next Quarterly Earnings Report

DexCom will release its first-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Is DexCom Stock Underperforming the Dow?

DexCom significantly underperformed the Dow over the past year, yet analysts remain strongly bullish on the stock’s long term prospects.

DexCom Stock Outlook: Is Wall Street Bullish or Bearish?

Although DexCom has significantly lagged behind the broader market over the past year, Wall Street analysts remain strongly optimistic about the stock's prospects.

1 2 3

People

Robert F. Kennedy Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Food and Drug Administration

Abbott Laboratories

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

399,440 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play